Epstein–Barr virus peptide–Major Histocompatibility Complex (EBV pMHC)

Epstein–Barr virus (EBV) peptide–Major Histocompatibility Complex (pMHC) complexes are molecular structures presented on the surface of cells infected with EBV or transformed into malignant states by the virus (Source: PubMed, PMID: 30555550). These complexes consist of short viral peptides derived from EBV proteins—such as Latent Membrane Proteins (LMP1, LMP2) or EBV Nuclear Antigens (EBNA)—bound within the groove of MHC (HLA) molecules (Source: UniProt). Their primary biological function is to signal the presence of intracellular viral infection to the immune system, specifically to CD8+ cytotoxic T lymphocytes (Source: NIH). In the context of EBV-associated malignancies like nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (PTLD), these pMHC complexes serve as highly specific therapeutic targets (Source: Lancet Oncology). Modern immunotherapies, including adoptive T-cell transfers like tabelecleucel (Ebvallo) and TCR-engineered T cells, are designed to recognize these specific complexes to selectively eliminate tumor cells while sparing healthy tissue (Source: EMA). However, therapeutic efficacy can be challenged by viral immune evasion strategies, such as the downregulation of HLA molecules or the selection of peptide variants (Source: Nature Reviews Cancer).

Other names

EBV peptide-HLA complexEBV antigen-MHC complexEpstein-Barr virus pMHCEBV-specific pMHC

T-cell receptor (TCR) mediated recognition of viral peptides presented by MHC molecules, leading to targeted cytotoxic T-lymphocyte (CTL) activation and lysis of the target cell.